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Abstract
Prothrombin G20210A gene variant (FII G20210A) is a risk factor for venous thrombotic disease
while conflicting results have been reported for the risk of arterial thrombotic events. However,
vascular episodes were absent in up to 40% of the 67 homozygotes for the G20210A described so
far, which indicates that the clinical expression depends on additional risk/trigger factors. We
describe six homozygotes for the G20210A variant, among which the first pair of siblings (cases n.
3 and 4) reported so far that displayed a strongly heterogeneous clinical outcome. Case 1, a female
of 27 years, developed a full thrombosis of common femoral, superficial and popliteal veins. She
assumed oral contraceptives in the last two years. Case n. 2, 34 years old, suffered of recurrent
pregnancy loss in absence of any causative alteration. Cases n. 3 and n. 5 experienced arterial
thrombotic disease, i.e., juvenile myocardial infarction (40 years old) and stroke (48 years old),
respectively, in absence of other risk factors. Finally, cases n. 4 and 6 identified as homozygotes for
the FII G20210A variant being consanguineous of symptomatic subjects bearing the variant, did not
experience any episode of venous nor arterial disease. Both of them have chronic liver disease with
an impairement of the prothrombin time INR. Thus, homozygotes for the G20210A are at risk for
arterial (in addition to venous) thromobotic events; chronic liver disease might modulate this risk.
Background
The G20210A variant in the 3' UTR of prothrombin gene
(FII G20201A) is associated with higher plasma pro-
thrombin activity and has a prevalence of 1.2–4.6% in the
general Caucasian population, and higher in patients
affected by venous thromboembolism (VTE, [1,2]). Heter-
ozygotes for the variant have an odds ratio for VTE ranging
from 2 to 4 [3]. On the contrary, conflicting results have
been reported for the risk of arterial thrombotic events in
subjects bearing the G20210A variant [4-15]. The high
incidence of the G20210A variant in the general popula-
tion and a large-cohort meta-analysis suggest that hetero-
zygosity for G20210A is a mild prothrombotic factor [10].
On the other hand, vascular episodes were absent in up to
40% of the 67 homozygotes for the G20210A described
so far [3], which suggests that clinical expression in sub-
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jects bearing inherited thrombophilia appear only in the
presence of additional risk factors [3,11]. The clinical his-
tory of six homozygotes for the FII G20210A variant stud-
ied by our group, among which the first pair of siblings
described so far, indicates that the clinical outcome of
these subjects is strongly heterogeneous, and that both
trigger and protective factors may be involved.
Case reports
Case 1
female, current age 27 years. She takes oral contraceptives
since the last two years. Few weeks ago color Doppler
revealed a full thrombosis of common femoral, superfi-
cial and popliteal veins of right leg. Laboratory revealed
she was homozygote for FII G20210A, with a normal
activity of ATIII, PC and PS, the absence of the Factor V
Leiden (FVL) and methylenetetrahydrofolate reductase
(MTHFR) C677T variant and the absence of antiphos-
pholipid syndrome. Moreover, the patient did not show
further thrombotic risk factor as recent surgery, immobil-
ity, first degree relative affected by venous thromboembo-
lism, malignancy nor risk factor for arterial thrombosis as
smoking, hypertension, diabetes, dyslipidemia. After 4
months she is ongoing oral anticoagulation and dis-
charged pill.
Case 2
female, current age 34 years. She experienced 2 early preg-
nancy loss within the first 12 weeks and 1 late pregnancy
loss at 22 weeks of gestation. Her personal and familial
anamnesis were negative for previous thrombotic disor-
ders. Any alteration that may explain recurrent pregnancy
loss (i.e. uterine malformations, chromosomal altera-
tions, endocrinological diseases, infective gynaecological
or systemic diseases, chronic inflammatory diseases) was
absent. She was homozygote for FII G20210A, without
other laboratory alterations (i.e. PC, PS or ATIII deficien-
cies, FVL or MTHFR variants, anticardiolipin antibodies
and lupus anticoagulant). Also this patient did not show
further thrombotic risk factor as personal history of
venous thromboembolism as recent surgery as recent
immobility as first degree relative affected by venous
thromboembolism as malignancy nor risk factor for arte-
rial thrombosis as smoking as hypertension, diabetes, dys-
lipidemia. The patient actually does not take any type of
antithrombotic treatment and of course she was invited to
perform thromboprophylaxis in presence of further tran-
sient thrombotic risk factor.
Cases 3 and 4
case 3 is a male, current age: 42 years. At the age of 40
years he had an acute myocardial infarction (AMI). His
mother died at 36 years of age from AMI and his father
died at 58 years of age from hepatocellular carcinoma on
cirrhosis. He is a non-smoker and diabetes, dyslipidemia
and hypertension were excluded as risk factors for venous
thromboembolism as recent surgery, immobility and
malignancy. The remote anamnesis was negative for
venous and arterial thrombotic diseases. Laboratory
showed normal activity of ATIII, PC and PS, the absence
of the FVL and heterozygosis for the MTHFR C677T vari-
ant with normal serum levels of homocysteine (Hcy). He
was homozygote for FII G20210A variant. After the
screening for thrombophilia his antithrombotic treatment
was changed and actually based on the association of oral
anticoagulation, with International Normalized Ratio,
(INR, [12]), ranged between 2.0 and 3.0, and low doses of
aspirin (i.e. 100 mg daily). Further, clinical, instrumental
and laboratory findings excluded any liver disease. After
genetic counselling, molecular analysis was extended to
the family, and the patient's brother, case n. 4, current age
48 years old, was found to be homozygote for FII
G20210A too. Anamnesis, clinical examination and
instrumental tests (i.e. electrocardiography, echocardiog-
raphy and vascular ultrasound scan of the carotid and
lower limbs) excluded any vascular disease. Moreover,
besides familial trend to thrombotic events and presence
of inherited thrombophilia, as for his brother, further
thrombotic risk factors for venous and\or arterial throm-
bosis were absent (see above). From the age of 21 years,
he assumed high amounts of alcohol and developed liver
cirrhosis, currently Child-Pugh stage B [16], with a pro-
thrombin INR of 1.9. None antithrombotic treatment was
suggested for him.
Case 5
female, current age: 60 years old. Both parents died when
she was a child, the mother for AMI, the father for an
unknown disease. Remote anamnesis was negative for
thrombotic diseases and for atherothrombosit risk factors
as smoking, alcohol, diabetes, dyslipidemia, hypertension
and pharmacological and hormonal therapies. Similarly,
risk factors for venous thrombosis as recent immobility,
malignancy and recent surgery were absent. At the age of
48 years, she experienced an episode of left hemiparesis.
Computerized tomography scan showed hypodensity in
the talamus and in the motor cortical area. Carotidal and
vertebral vascular ultrasound scan associated to color-
Doppler, and ECG and echocardiography were negative.
The patient was successfully treated with antithrombotic
therapy. Laboratory demonstrated homozygosity for the
FII G20210A gene variant, whereas other data (i.e., AT III,
PC, PS, homocysteinemia, FVL and MTHFR variants) were
normal. The antithrombotic therapy based on oral antico-
agulation (INR range 2.0–3.0) is ongoing again and 12
years later (today), the patient did not refer any other
thrombotic episode.Journal of Translational Medicine 2008, 6:36 http://www.translational-medicine.com/content/6/1/36
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Case 6
male, current age: 40 years. This patient came to our atten-
tion because his sister, who suffered from recurrent abor-
tions, was heterozygous for the FII G20210A variant. After
genetic counselling, the analysis was extended to all first-
degree relatives and he resulted to be homozygous for
G20210A. All other laboratory data (i.e., AT III, PC, PS,
FVL and MTHFR C677T variant) were normal. His father
died at 40 years from AMI; his mother (heterozygote for
FII G20210A) had never suffered from vascular diseases.
The patient is a non-smoker, without hypertension, diabe-
tes and\or dyslipidaemia; thrombotic risk factors for
venous thromboembolism were also absent as recent sur-
gery as recent immobility as malignancy and its therapies
as previous personal history of venous thrombosis.
Remote and recent anamnesis are negative for vascular
diseases and these data were confirmed by a clinical exam-
ination and additional tests (i.e. electrocardiography,
echocardiography and vascular ultrasound scan of carotid
and lower limbs). The patient has a 20-year history of
intravenous drug assumption (mainly heroin) and is
affected by chronic viral hepatitis C and Child-Pugh stage
A cirrhosis with a INR < 1.7 [16]. No episode of vascular
disease occurred during the last 4 years and none anti-
thrombotic treatment was suggested for him.
Discussion
Two of the six described cases homozygotes for the
G20210A prothrombin variant experienced a deep vein
thrombosis during oral contraceptive use (one of them)
and recurrent pregnancy loss (the other one). Two other
had an acute thrombotic arterial event. The last two, bear-
ing the same genotype, did not experience any thrombotic
arterial nor venous disease, and both were affected by
chronic liver disease with an altered prothrombin activity.
The first two cases confirm the well known association
between inherited thrombophilia and venous throm-
boembolism and\or recurrent pregnancy loss [17,18].
Case n. 1 was a young woman and had a deep vein throm-
bosis of lower limb after two years of oral contraceptive
use. Indeed, several studies described the early onset of
venous thromboembolism in subjects bearing inherited
thrombophilia [17] and the trigger action of oral contra-
ceptives in particular in subjects with already known
thrombophilia [19]. Similarly, the relationships between
inherited thrombophilia and pregnancy loss are well
known [18]. Our patient experienced three consecutive
pregnancy losses without any known clinical, anatomic or
genetic alterations causing adverse pregnancy outcomes
other than the homozygosity for FII G20210A variant.
Interestingly, the patient suffered of two episodes of early
recurrent pregnancy losses and one episode of late preg-
nancy loss that are more frequently associated to inherited
thrombophilia [18]. Furthermore, our cases support that
the homozygosis for the FII G20210A variant may be a
risk factor also for arterial thrombotic events besides of
venous thromboembolism. Both the patients who experi-
enced arterial thrombotic diseases had a parent who died
from AMI and thrombotic episodes occurred at a rela-
tively young age (40 and 48 years, respectively). Furtherly,
they did not have other common risk factors for throm-
botic arterial disease such as smoking, hypertension, dia-
betes, dyslipidemia [20]. Conflicting data have been
reported so far on the relationships between inherited
thrombophilia and arterial thrombotic diseases [4-15]. A
higher risk of AMI in young women carrying FII G20210A
variant and an association between G20210A and coro-
nary heart disease were reported. Other retrospective and
prospective studies excluded that the G20210A variant
may predispose to arterial thrombotic diseases. G20210A
was not associated to an increased risk of infarction or
stroke in a prospective study of 15,000 males [15], while
a meta-analysis involving 66,000 cases and 91,000 con-
trols indicated that the G20210A variant was associated to
a moderately increased risk of coronary diseases [10].
Finally, other two described cases suggest that chronic
liver disease may mitigate the risk of vascular disease in
patients bearing the G20210A genotype. This information
may be found as an innovative point of view on the gene-
enviroment relationships existing in the pathogenesis of
thrombotic diseases. In fact, patients 4 and 6, who did not
have a history of vascular diseases, had liver disease (i.e.,
Child B and Child A cirrhosis in cases 4 and 6 respec-
tively). Liver cirrhosis is typically associated to impaired
synthesis [21] and post-translational maturation [22,23]
of clotting factors, which increases the trend to develop
hemorrhagic complications as acute gastrointestinal
bleedings [24]. Consequently, these biochemical altera-
tions may counteract the increase of prothrombin levels
and activity that are associated to the G20210A variant
[25]. Indeed, patients 4 and 6 had reduced INR according
to the hypocoagulability due to the impaired liver func-
tion. In this setting it must be underlined that patients 5
and 6 were identified as homozygotes for FII G20210A
being consanguineous of other affected subjects, and this
evidence reinforces the role of the genetic counselling to
the families, and the concept to extend molecular analysis
to consanguineous once a symptomatic subject bearing
inherited thrombophilia is identified. In conclusion, our
cases support the idea that the G20210A homozygote gen-
otype associated to another thrombotic risk factor acting
as trigger factor is sufficient to give vascular complications
as venous thromboembolism and\or female infertility
[17,18]; moreover, inherited thrombophilia and in partic-
ular the prothrombin A20210G variant is a relevant risk
factor for recurrent pregnancy loss. On the other hand
prothrombin A20210G may be also a risk factor for arte-
rial disease, as AMI, in particular if early onset and familial
anamnesis were positive also in absence of further risk fac-Journal of Translational Medicine 2008, 6:36 http://www.translational-medicine.com/content/6/1/36
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tors for arterial disease. Furthermore, although data need
to be confirmed on a larger population, we suggest also
that concomitant hypocoagulation, due to impaired liver
function, may reduce the risk of venous and arterial
thrombotic disease in homozygotes for the G20210A pro-
thrombin variant.
Conclusion
So, due to the lacking data available in the Literature, our
case series underlined that the natural history of subjects
carrying A20210G variant of prothrombin may be diffi-
cult to be evaluated in such situation. Relevant clinical
aspect that should be considered are related to the strong
association with repeated pregnancy loss and venous
thromboembolism, in particular if further risk factor is
present. On the other hand, other clinical aspects that
should be considered also by further studies are the possi-
ble association with arterial thrombosis in pres-
ence\absence of further risk factor for atherothrombosis
and the role of comorbidities with a trend toward hypoco-
agulation that may mitigate thrombotic trend as liver dys-
function in our cases.
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